Critical Survey: Nabriva Therapeutics (NASDAQ:NBRV) versus Sophiris Bio (NASDAQ:SPHS)

Nabriva Therapeutics (NASDAQ:NBRV) and Sophiris Bio (NASDAQ:SPHS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Nabriva Therapeutics and Sophiris Bio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nabriva Therapeutics 0 1 6 0 2.86
Sophiris Bio 0 0 3 0 3.00



Nabriva Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 227.87%. Sophiris Bio has a consensus target price of $4.83, indicating a potential upside of 369.26%. Given Sophiris Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Sophiris Bio is more favorable than Nabriva Therapeutics.

Valuation & Earnings

This table compares Nabriva Therapeutics and Sophiris Bio’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nabriva Therapeutics $9.66 million 243.98 -$114.78 million ($1.63) -1.50
Sophiris Bio N/A N/A -$6.78 million ($0.52) -1.98

Sophiris Bio has lower revenue, but higher earnings than Nabriva Therapeutics. Sophiris Bio is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Nabriva Therapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500. Comparatively, Sophiris Bio has a beta of 2.8, indicating that its share price is 180% more volatile than the S&P 500.

Insider and Institutional Ownership

3.0% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 8.3% of Sophiris Bio shares are held by institutional investors. 3.3% of Nabriva Therapeutics shares are held by company insiders. Comparatively, 4.5% of Sophiris Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Nabriva Therapeutics and Sophiris Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nabriva Therapeutics -3,194.72% -119.75% -86.80%
Sophiris Bio N/A -5,789.95% -90.93%

Summary

Sophiris Bio beats Nabriva Therapeutics on 8 of the 13 factors compared between the two stocks.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Sophiris Bio Company Profile

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.